Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Ferumoxytol' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Ferumoxytol' found in 1 term [] and 4 definitions []
1 - 5 (of 5)     
Result Pages : [1]
Searchterm 'Ferumoxytol' was also found in the following services: 
spacer
News  (13)  Resources  (2)  
 
FerumoxytolInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Ferumoxytol is a product candidate for iron replacement therapy in the development pipeline of AMAG Pharmaceuticals Inc, formerly known as Code 7228.
Ferumoxytol has a long blood half-life and may be useful as a blood pool agent in a wide range of applications in MRI. Ferumoxytol is a true intravascular contrast agent that remains in the blood stream for an extended period of time.
spacer
 
• Share the entry 'Ferumoxytol':  Facebook  Twitter  LinkedIn  
 
• Related Searches:
    • MS-325
    • Superparamagnetic Iron Oxide
    • Relaxivity
    • Very Small Superparamagnetic Iron Oxide Particles
    • AMAG Pharmaceuticals, Inc.
 
Further Reading:
  News & More:
Diffusion-weighted MRI shows promise as a radiation-free alternative for pediatric tumor staging
Wednesday, 19 February 2014   by www.2minutemedicine.com    
Rienso® (Ferumoxytol) Launched in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease Launch Triggers $15 Million Milestone Payment to AMAG
Monday, 5 November 2012   by ir.amagpharma.com    
MRI Resources 
Open Directory Project - Absorption and Emission - Shoulder MRI - PACS - MRI Technician and Technologist Career - Crystallography
 
Code 7228InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Code 7228, generic name: Ferumoxytol, central moiety: Fe
Code 7228 is the code name for a substance in the development pipeline (AMAG Pharmaceuticals, Inc.) for use as a contrast agent in magnetic resonance angiography (MRA). Ferumoxytol, as a true blood pool agent, resides in the vascular space for an extended period of time and does not leak out into adjacent tissues like currently used gadolinium-based contrast agents. The product is being evaluated in MRA applications for the detection of blood flow in the heart muscle, in exploratory studies for the diagnosis of vulnerable plaque and as a next generation lymph node agent.
Code 7228 is currently in approval phase for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoetin.
It is presently contemplated that Ferumoxytol will compete with the contrast agents Vasovist™ from EPIX Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham.

spacer

• View the DATABASE results for 'Code 7228' (4).Open this link in a new window

 
Further Reading:
  Basics:
Ferumoxytol
   by www.amagpharma.com    
MRI Resources 
Fluorescence - Collections - Spectroscopy pool - Manufacturers - Knee MRI -
 
AMAG Pharmaceuticals, Inc.MRI Resource Directory:
 - Developers -
 
www.amagpharma.com The company changed its name from Advanced Magnetics, Inc. to AMAG Pharmaceuticals, Inc. in July 2007.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, developed and manufactured organ-specific diagnostic contrast agents that provide clearer images during magnetic resonance imaging (MRI) tests used to detect tumors and other abnormalities.
The company had two MRI related products on the market: Feridex I.V. (for the diagnosis of liver lesions) and GastroMARK (used for bowel and abdominal MR imaging). In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex. The development of Combidex as a contrast agent for lymph disease has also been stopped.
The Company has now two commercial products: Feraheme® and GastroMARK®. Feraheme® is the trade name of Ferumoxytol (formerly Code 7228) and is indicated for the treatment of iron deficiency anemia. Feraheme® is also being developed as a diagnostic agent for vascular-enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Combidex® -
Feridex® -
GastroMARK®
Feraheme®

Contact Information
MAIL AMAG Pharmaceuticals, Inc.
61 Mooney St.
Cambridge, MA 02138
USA
PHONE +1-617-497-2070
FAX +1-617-547-2445
E-MAIL contactus@amagpharma.com
ONLINE www.amagpharma.com

spacer

• View the DATABASE results for 'AMAG Pharmaceuticals, Inc.' (10).Open this link in a new window


• View the NEWS results for 'AMAG Pharmaceuticals, Inc.' (7).Open this link in a new window.
 
Further Reading:
  Basics:
Advanced Magnetics, Inc. Announces Name Change to AMAG Pharmaceuticals, Inc.
Tuesday, 24 July 2007   by salesandmarketingnetwork.com    
Ferumoxytol
   by www.amagpharma.com    
AMAG Pharmaceuticals Inc. Q4 2008 Earnings Call Transcript
Friday, 27 February 2009   by seekingalpha.com    
  News & More:
The demise of Combidex - Sinerem
Wednesday, 24 March 2010   by www.wellsphere.com    
Searchterm 'Ferumoxytol' was also found in the following services: 
spacer
News  (13)  Resources  (2)  
 
MS-325Forum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.
See also Classifications, Characteristics, etc.
spacer

• View the DATABASE results for 'MS-325' (4).Open this link in a new window


• View the NEWS results for 'MS-325' (10).Open this link in a new window.
 
Further Reading:
  News & More:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
MRI Resources 
General - Portals - Anatomy - Nerve Stimulator - Raman Spectroscopy - Developers
 
NC100150 InjectionInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™(1)
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection is discontinued.


1. IMPORTANT: The trade name Clariscan™ planned to be used at the time of Amersham Health is reused (since 2017) for a contrast agent developed by GE Healthcare. The newly developed Clariscan™ by GE Healthcare is a totally different contrast agent with first approvals in March of 2017. Please read Clariscan™.
spacer

• View the DATABASE results for 'NC100150 Injection' (5).Open this link in a new window


• View the NEWS results for 'NC100150 Injection' (2).Open this link in a new window.
MRI Resources 
Online Books - Coils - Hospitals - Mobile MRI - Contrast Agents - Blood Flow Imaging
 
     1 - 5 (of 5)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Acoustic Noise Reduction (Silent, Quiet, etc.) :
cannot get better 
is in its first steps 
is done by earplugs, headphones 
must get better 
is bad, I miss something 
is unnecessary 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 17 February 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]